Inhaled imatinib for advanced lung disease before or after transplant
Part of Lungs & breathing clinical trials.
This trial tests whether a special inhaled form of the medicine imatinib can help people with advanced lung scarring or high blood pressure in the lungs. It is designed for those who are on the path to a lung transplant or already received one.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have fibrosing lung disease, obliterative bronchiolitis, or pulmonary arterial hypertension (PAH).
- You are being considered for a lung transplant or have already had one.
- You must not have any current or suspected lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This study is for people who have completed an earlier clinical trial for pulmonary fibrosis. It checks the long-term safety and tolerability of the study drug.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This Phase 2 trial is for adults with pulmonary hypertension who are on the lung transplant waiting list at Duke. It aims to test whether the study treatment can improve lung pressure and related health outcomes, while using things like MRI to monitor changes.
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
This study tests a treatment for a rare lung condition called fibrosing mediastinitis, where scar tissue in the chest presses on the lung artery, causing high blood pressure in the lungs. The goal is to see if the treatment can improve your symptoms and quality of life.
Hear when a new Lung Fibrosis Interstitial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.